



Order ID 203283
Provider Exagen, Inc.

Specimen	Patient
Collected 01/06/2018	Sandra, Clark
Received 01/07/2018	170104.1
Test Order	Gender - DOB Male - 01/04/1984
Created 01/12/2018	Identifier Received
Reported 01/12/2018	Exagen ID 302243


AVISE MTX Test Report

Current Methotrexate Polyglutamate (MTXPG) Level:

62.0 nmol/L RBC equivalent - Therapeutic

Date Current Dose Initiated	Current Dose	Date MTX Initiated
1/6/2018	10	8/8/2014

Current and Prior 5 MTXPG Levels



MTXPG Level	Interpretation & Consideration
Therapeutic (>60 nmol/L)	Patient is metabolizing MTX effectively. Level is consistent with clinical efficacy
Intermediate (20-60 nmol/L)	Patient may need more exposure to MTX
Sub-therapeutic (<20 nmol/L)	Patient may not be metabolizing MTX effectively or patient may be non-compliant with therapy

Date	4/6/2017	7/6/2017	10/6/2017	1/6/2018
Level	22.2 †	32.1 ‡	44.4 †	62.0 ‡
Dose	10	10	10	10

†nmol/L RBC
‡nmol/L RBC equivalent

Test Method Description

AVISE MTX measures red blood cell methotrexate polyglutamates, the active metabolites of methotrexate as an aid in optimizing methotrexate dose and therapeutic efficacy in the treatment of rheumatoid arthritis. In a cohort of 256 rheumatoid arthritis patients taking methotrexate (range 5-25 mg/wk, median 15 mg/wk) for more than 3 months, those with a MTXPG level below 20 nmol/L were 3-fold more likely to have a poor response to methotrexate vs. those with level ≥ 20 nmol/L (OR =2.9; 95% CI:1.4-5.9). Those with a MTXPG level above 60 nmol/L were 5-fold more likely to have a good response to methotrexate vs. those with level ≤ 60 nmol/L (OR=5.5; 95% CI:2.5-12.0).

The MTXPG level is obtained by a liquid chromatographic method coupled with tandem mass spectrometry. The concentration from venous blood is expressed as nmol/L packed red blood cells (RBC). The concentration determined from whole capillary blood is expressed as nmol/L RBC equivalent. Studies supporting the clinical utility of this test are based on patients receiving methotrexate for at least 3 months. Caution should be used in interpreting results for patients on therapy for less than three months.

References

- Dervieux T, Furst D, et al. Polyglutamation of Methotrexate With Common Polymorphisms in Reduced Folate Carrier, Aminoimidazole Carboxamide Ribonucleotide Transformylase, and Thymidylate Synthase Are Associated With Methotrexate Effects in Rheumatoid Arthritis, Arthritis Rheum. 2004; 50(9):2766-2774.
- Dervieux T, Furst D, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross sectional observational study, Ann Rheum Dis 2005;64(8):1180-1185.
- Dervieux T, Greenstein N, et al. Pharmacogenomic and Metabolic Biomarkers in the Folate Pathway and Their Association With Methotrexate Effects During Dosage Escalation in Rheumatoid Arthritis, Arthritis Rheum. 2006;54(10):3095-3103.
- Kremer J, Toward a Better Understanding of Methotrexate, Arthritis Rheum. 2004;50(5):1370-1382.



1261 Liberty Way, Vista CA
CLIA# 05D1075048
CAP# 7201051 | PFI# 8369

Laboratory Directors:
Richard Safrin, MD
Thierry Dervieux, PhD, DABCC

Provider Relations: 888.452.1522

AVISE and the AVISE and Exagen logos are registered trademarks of Exagen, Inc. ©2019 All Rights Reserved

This test is used for clinical purposes, though results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research. It has not been cleared or approved by the FDA. Exagen is regulated under CLIA as qualified to perform high-complexity testing. SA1045 (9/16)